The Lancet · Randomized Controlled Trial · 2026-07-15
Strong EvidenceBeta-lactam allergy delabeling via direct oral challenge in low-risk patients: a randomized trial
Why it matters. A concrete stewardship lever, delabeling expands access to preferred, narrower agents.
Study design
- Design
- Multicenter RCT
- Population
- Low-risk penicillin-allergy-labeled adults
- Setting
- Multi-site
- Sample size
- n = 900
- Intervention
- Direct oral amoxicillin challenge
- Comparator
- Standard skin testing pathway
Provenance
- Source
- The Lancet
- Source type
- peer_reviewed
- Content analyzed
- abstract
Evidence grading reflects the portion of the source actually analyzed. Always confirm against the original before acting.
Your read
Post your interpretation for colleagues. Every post stays anchored to this source, no empty-box updates.
Sign in to post your read of this evidence.